Migdal Insurance & Financial Holdings Ltd. Raises Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Migdal Insurance & Financial Holdings Ltd. raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 6.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,919,540 shares of the company's stock after acquiring an additional 1,860,000 shares during the quarter. Teva Pharmaceutical Industries makes up 6.1% of Migdal Insurance & Financial Holdings Ltd.'s holdings, making the stock its 2nd largest holding. Migdal Insurance & Financial Holdings Ltd. owned about 2.58% of Teva Pharmaceutical Industries worth $301,920,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in shares of Teva Pharmaceutical Industries by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 1,875,394 shares of the company's stock valued at $17,609,000 after acquiring an additional 28,920 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Teva Pharmaceutical Industries by 12.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company's stock valued at $1,118,000 after purchasing an additional 13,069 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 4.7% in the 1st quarter. MetLife Investment Management LLC now owns 95,953 shares of the company's stock worth $901,000 after buying an additional 4,300 shares during the period. BlackRock Inc. grew its position in shares of Teva Pharmaceutical Industries by 3.7% during the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company's stock worth $391,081,000 after buying an additional 1,494,814 shares in the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in shares of Teva Pharmaceutical Industries by 4.0% during the first quarter. Great West Life Assurance Co. Can now owns 420,533 shares of the company's stock valued at $4,137,000 after buying an additional 16,134 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Up 0.8 %

Teva Pharmaceutical Industries stock traded up $0.10 during trading on Wednesday, hitting $13.19. The company had a trading volume of 6,571,551 shares, compared to its average volume of 10,709,397. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. The company's 50 day simple moving average is $13.45 and its 200-day simple moving average is $11.21. Teva Pharmaceutical Industries Limited has a 1-year low of $7.09 and a 1-year high of $14.47. The stock has a market cap of $14.79 billion, a price-to-earnings ratio of -27.85, a price-to-earnings-growth ratio of 1.59 and a beta of 1.05.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The company had revenue of $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 target price for the company in a report on Friday, March 8th. Barclays lifted their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an "overweight" rating in a research note on Monday, February 5th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 1st. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Finally, The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a research note on Monday, February 5th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus target price of $13.78.

Insider Buying and Selling

In other news, CAO Amir Weiss sold 31,766 shares of the company's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the transaction, the chief accounting officer now owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the transaction, the chief accounting officer now owns 10,676 shares in the company, valued at $132,062.12. The disclosure for this sale can be found here. Insiders sold 390,738 shares of company stock worth $5,132,766 over the last 90 days. 0.62% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.